Study #2021-0076
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
MD Anderson Study Status
Not Accepting
Treatment Agent
Cetuximab, Expanded CB-NK cells, Fludarabine phosphate, Cyclophosphamide
Description
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colon Cancer, Resected Stage
Study phase:
Phase I
Physician name:
Maria Pia Morelli
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-478-0144
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.